Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.

Autor:	van Meurs HS; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., van der Velden J; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., Buist MR; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., van Driel WJ; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Kenter GG; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., van Lonkhuijzen LR; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2015 Nov; Vol. 94 (11), pp. 1269-75. Date of Electronic Publication: 2015 Sep 15.
DOI:	10.1111/aogs.12720
Abstrakt:	Introduction: The aim of this study was to retrospectively determine the objective response rate to hormone therapy (HT) for patients with a measurable adult granulosa cell tumor (GCT) of the ovary in a consecutive series of patients. Material and Methods: All patients with an adult GCT who were treated with HT [steroidal progestins, selective estrogen receptor modulators, aromatase inhibitors and gonadotropin-releasing hormone agonists] within three referral hospitals were identified and their records were screened for HT administration. The main outcome measure was the objective response rate to HT. Results: We identified 127 patients with an adult GCT, of whom 81 (64%) had a recurrence. Twenty-five of these patients (20%) were treated with hormones, of whom 22 had measurable disease at the start of their treatment, i.e. a tumor of more than 1 cm in diameter as seen on imaging, either as a recurrence or as residual disease. The pooled objective response rate, defined as the proportion of patients whose best overall response to hormone therapy was either complete response or partial response to HT, was 18% (4/22) (95% confidence interval 6-41%). In one patient (4.5%) a complete response and in three (14%) a partial response was described. Fourteen patients (64%) had stable disease and in four patients (18%) disease was progressive. Conclusions: Although several case reports described good responses to HT in patients with a GCT, we found a response in only four of 22 patients in this relatively large consecutive series of patients. (© 2015 Nordic Federation of Societies of Obstetrics and Gynecology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu